Inhalation treatment with glutathione in patients with cystic fibrosis: A randomized clinical trial

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 1, 2013, Pages 83-89

  Griese, Matthias ^a   Kappler, Matthias ^a   Eismann, Claudia ^a   Ballmann, Manfred ^b   Junge, Sibylle ^b   Rietschel, Ernst ^c   Van Koningsbruggen Rietschel, Silke ^c   Staab, Doris ^d   Rolinck Werninghaus, Claudia ^d   Mellies, Uwe ^e   Köhnlein, Thomas ^b   Wagner, Thomas ^f   König, Susanne ^g   Teschler, Helmut ^h   Heuer, Hans Eberhard ⁱ   Kopp, Matthias ^j   Heyder, Susanne ^k   Hammermann, Jutta ^l   Küster, Peter ^m   Honer, Marguerite ⁿ   Mansmann, Ulrich ^a   Beck Speier, Ingrid ^o   Hartl, Dominik ^p   Fuchs, Carola ^q   Hector, Andreas ^p   more..

^a UNIVERSITY OF MUNICH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g ST JOSEF HOSPITAL   (Germany)

^h RUHRLANDKLINIK   (Germany)

ⁱ Gemeinschaftspraxis Friesenweg   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^l UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^m Clemenshospital Munster   (Germany)

ⁿ Mukoviszidose eV   (Germany)

^o Institute for Inhalation Biology   (Germany)

^p UNIVERSITY OF TÜBINGEN   (Germany)

^q Pari Pharma GmbH   (Germany)

more..

Author keywords

Antioxidant; Clinical trial; Cystic fibrosis; Glutathione; Inhaled therapy

Indexed keywords

GLUTATHIONE; LIPID; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG FEVER; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; LUNG FUNCTION; MULTICENTER STUDY; NEBULIZER; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SPUTUM ANALYSIS; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADULT; ANTIOXIDANTS; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GLUTATHIONE; HUMANS; MALE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880170145     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201303-0427OC     Document Type: Article

References (29)

1. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011;184:75-81.
2. Hartl D, Gaggar A, Bruscia E, Hector A, Marcos V, Jung A, Greene C, McElvaney G, Mall M, Döring G. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012;11:363-382.
3. Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, Iuliano L, Piroddi M, Dechecchi MC, Cabrini G; Working Group on Inflammation in Cystic Fibrosis. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta 2012;1822:690-713.
4. Cantin AM, White TB, Cross CE, Forman HJ, Sokol RJ, Borowitz D. Antioxidants in cystic fibrosis: conclusions from the CF Antioxidant Workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic Biol Med 2007;42:15-31. (Pubitemid 44842010)
5. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993;75: 2419-2424. (Pubitemid 24008354)
6. Roum JH, Borok Z, McElvaney NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 1999;87:438-443. (Pubitemid 29330711)
7. Griese M, Ramakers J, Krasselt AI, Starosta V, Van Koningsbruggen S, Fischer R, Ratjen F, Müllinger B, Huber RM, Maier K, et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 2004;169:822-828. (Pubitemid 38402458)
8. Hudson VM. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 2001;30:1440-1461. (Pubitemid 32522959)
9. Hull J, Vervaart P, Grimwood K, Phelan P. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 1997;52:557-560. (Pubitemid 27298509)
10. Linsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Physiol 1998;275:C323-C326.
11. Gao L, Kim KJ, Yankaskas JR, Forman HJ. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol 1999;277:L113-L118. (Pubitemid 29356757)
12. Gould NS, Gauthier S, Kariya CT, Min E, Huang J, Brian DJ. Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Respir Res 2010;11:119.
13. Dauletbaev N, Viel K, Buhl R, Wagner TO, Bargon J. Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis. J Cyst Fibros 2004;3:119-124. (Pubitemid 38987022)
14. Bishop C, Hudson VM, Hilton SC, Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005;127:308-317. (Pubitemid 41724591)
15. Visca A, Bishop CT, Hilton SC, Hudson VM. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. J Cyst Fibros 2008;7:433-436.
16. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME; The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642. (Pubitemid 24276863)
17. Wenninger K, Aussage P, Wahn U, Staab D; German Cystic Fibrosis Questionnaire Study Group. The revised German Cystic Fibrosis Questionnaire: validation of a disease-specific health-related quality of life instrument. Qual Life Res 2003;12:77-85. (Pubitemid 36223008)
18. Hector A, Jonas F, Kappler M, Feilcke M, Hartl D, Griese M. Novel method to process cystic fibrosis sputum for determination of oxidative state. Respiration 2010;80:393-400.
19. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, Thompson S, Bush A, Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358:1316-1321. (Pubitemid 33016495)
20. Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, Durham TA, Ramsey BW; TIGER-1 Investigator Study Group. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011;183:627-634.
21. Ren CL. Cystic fibrosis: evolution from a fatal disease of infancy with a clear phenotype to a chronic disease of adulthood with diverse manifestations. Clin Rev Allergy Immunol 2008;35:97-99.
22. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al.; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
23. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of longterm inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240. (Pubitemid 43113028)
24. Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, et al.; CF302 Investigators. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185:645-652.
25. Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011;140:425-432.
26. Fuchs C, Eismann C, Griese M, Seemann S, Knoch M. Use of patient monitoring systems in clinical trials to generate objective information on patients' drug adherence of inhaled medications [abstract]. J Cyst Fibros 2011;10:S91.
27. Buhl R, Holroyd K, Borok Z, Roum J, Bokser A, Grimes G. Reversal of the glutathione deficiency in the lower respiratory tract of HIVseropositive individuals by gutathione aerosol therapy. Abstr Clin Res 1990;38:596A.
28. Corti A, Franzini M, Cianchetti S, Bergamini G, Lorenzini E, Melotti P, Paolicchi A, Paggiaro P, Pompella A. Contribution by polymorphonucleate granulocytes to elevated gamma-glutamyltransferase in cystic fibrosis sputum. PLoS One 2012;7:e34772.
29. Hudson VM. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med 2004;3:353-363.